Pavaki Capital Management’s Biogen BIIB Stock Holding History

Pavaki Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$756K	Hold	3,500	–	–	0.26%	68
2026 Q1	$642K	Hold	3,500	–	–	0.27%	63
2025 Q4	$616K	Buy	+3,500	New	+$572K	0.24%	57

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pavaki Capital Management's BIIB Position: Q2 2026 in Review

Pavaki Capital Management held its Biogen (BIIB) position steady in Q2 2026 at 3,500 shares worth $756K. The position accounts for 0.26% of the portfolio, ranked #68.

Pavaki Capital Management first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 981 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Pavaki Capital Management held 3,500 shares of Biogen worth $756K as of Q2 2026.
Pavaki Capital Management left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.26% of Pavaki Capital Management's portfolio in Q2 2026, its #68 holding.
Pavaki Capital Management first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
981 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.